Avadel Pharmaceuticals plc
AVDL
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.12B
Close$
$-0.62
102.8% downside
Current Fair Value
102.8% downsideOvervalued by 102.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.12 Billion |
|---|---|
| Enterprise Value | $2.08 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.51 |
| Beta | 1.31 |
| Outstanding Shares | 97,104,000 |
Return
| Return on Equity | -0.28% |
|---|---|
| Return on Assets | -0.14% |
| Return on Invested Capital | 4.42% |
Valuation & Multiples
| P/E Ratio | -7558.74 |
|---|---|
| PEG | 7501.59 |
| Price to Sales | 10.82 |
| Price to Book Ratio | 21.64 |
| Enterprise Value to Revenue | 8.38 |
| Enterprise Value to EBIT | 343.66 |
| Enterprise Value to Net Income | -7488 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.38 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 5, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 45.27% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.00%▼ 75.77% |
|---|---|
| Total Invested | $426▼ 100.00% |
| Investors Holding | 1▼ 225.00% |
ESG Score
No data
About Avadel Pharmaceuticals plc
CEO: Gregory Divis